Helix-Loop-Helix Protein p8, a Transcriptional Regulator Required for Cardiomyocyte Hypertrophy and Cardiac Fibroblast Matrix Metalloprotease Induction

REFERENCES

• Bradham, W. S., G. Moe, K. A. Wendt, A. A. Scott, A. Konig, M. Romanova, G. Naik, and F. G. Spinale. 2002. TNF-α and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am. J. Physiol. Heart Circ. Physiol. 282:H1288–H1295.
   PubMedGoogle Scholar
• Carracedo, A., M. Lorente, A. Egia, C. Blázquez, S. García, V. Giroux, C. Malicet, R. Villuendas, M. Gironella, L. González-Feria, M. A. Piris, J. L. Iovanna, M. Guzmán, and G. Velasco. 2006. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 9:301–312.
   PubMed Web of Science ®Google Scholar
• Chadee, D. N., M. J. Hendzel, C. P. Tylipski, C. D. Allis, D. P. Bazett-Jones, J. A. Wright, and J. R. Davie. 1999. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J. Biol. Chem. 274:24914–24920.
   PubMed Web of Science ®Google Scholar
• Choukroun, G., J. V. Bonventre, J. M. Kyriakis, A. Rosenzweig, and T. Force. 1998. Endothelin stimulation of cardiomyocyte hypertrophy requires the SAPK pathway. J. Clin. Investig. 102:1311–1320.
   PubMed Web of Science ®Google Scholar
• Choukroun, G., R. Hajjar, S. Fry, F. del Monte, S. Haq, J. L. Guerrero, M. Picard, A. Rosenzweig, and T. Force. 1999. Regulation of cardiac hypertrophy in vivo by the stress-activated protein kinases/c-Jun NH2-terminal kinases. J. Clin. Investig. 104:391–398.
   PubMed Web of Science ®Google Scholar
• Cross, D. A. E., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–789.
   PubMed Web of Science ®Google Scholar
• Davies, S. P., H. Reddy, M. Caivano, and P. Cohen. 2000. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351:95–105.
   PubMed Web of Science ®Google Scholar
• Dickens, M., J. S. Rogers, J. Cavanagh, A. Raitano, Z. Xia, J. R. Halpern, M. E. Greenberg, C. L. Sawyers, and R. J. Davis. 1997. A cytoplasmic inhibitor of the JNK signal transduction pathway. Science 277:693–696.
   PubMed Web of Science ®Google Scholar
• Dorn, G. W., and T. Force. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Investig. 115:527–537.
   PubMed Web of Science ®Google Scholar
• Ducharme, A., S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, L. E. Rohde, F. J. Schoen, R. A. Kelly, Z. Werb, P. Libby, and R. T. Lee. 2000. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Investig. 106:55–62.
   PubMed Web of Science ®Google Scholar
• Encinar, J. A., G. V. Mallo, C. Mizyrycki, L. Giono, J. M. Gonzalez-Ros, M. Rico, E. Canepa, S. Moreno, J. L. Neira, and J. L. Iovanna. 2001. Human p8 is a HMG-I/Y-like protein with DNA binding activity enhanced by phosphorylation. J. Biol. Chem. 276:2742–2751.
   PubMed Web of Science ®Google Scholar
• Goruppi, S., J. V. Bonventre, and J. M. Kyriakis. 2002. Signaling pathways and late-onset gene induction associated with renal mesangial cell hypertrophy. EMBO J. 21:5427–5436.
   PubMedGoogle Scholar
• Goruppi, S., and J. M. Kyriakis. 2004. The pro-hypertrophic bHLH protein p8 is degraded by the ubiquitin proteasome system in a protein kinase-B/Akt and glycogen synthase kinase-3-dependent manner, while endothelin induction of p8 mRNA and renal mesangial cell hypertrophy require NFAT4. J. Biol. Chem. 279:20950–20958.
   PubMedGoogle Scholar
• Hannan, R. D., V. Stefanovsky, L. Taylor, T. Moss, and L. I. Rothblum. 1996. Overexpression of the transcription factor UBF1 is sufficient to increase ribosomal DNA transcription in neonatal cardiomyocytes: implications for cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 93:8750–8755.
   PubMedGoogle Scholar
• Heymans, S., A. Luttun, D. Nuyens, G. Theilmeier, E. Creemers, L. Moons, G. D. Dyspersin, J. P. Cleutjens, M. Shipley, A. Angellilo, M. Levi, O. Nube, A. Baker, E. Keshet, F. Lupu, J. M. Herbert, J. F. Smits, S. D. Shapiro, M. Baes, M. Borgers, D. Collen, M. J. Daemen, and P. Carmeliet. 1999. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure after myocardial infarction. Nat. Med. 5:1135–1142.
   PubMed Web of Science ®Google Scholar
• Hoffmeister, A., A. Ropolo, S. Vasseur, G. V. Mallo, H. Boedeker, B. Ritz-Laser, G. R. Dressler, M. I. Vaccaro, J. C. Dagorn, S. Moreno, and J. L. Iovanna. 2002. The HMGI/Y-related protein p8 binds to p300 and Pax2 trans-activation-domain interacting protein to regulate the transactivation activity of the Pax2A and Pax2B transcription factors on the glucagon gene promoter. J. Biol. Chem. 277:22314–22319.
   PubMed Web of Science ®Google Scholar
• Hunter, J. J., and K. R. Chien. 1999. Signaling pathways for cardiac hypertrophy and failure. N. Engl. J. Med. 341:1276–1283.
   PubMed Web of Science ®Google Scholar
• Kang, P. M., and S. Izumo. 2003. Apoptosis in heart: basic mechanisms and implications in cardiovascular diseases. Trends Mol. Med. 9:177–182.
   PubMedGoogle Scholar
• Kyriakis, J. M. 2000. Mammalian MAP kinase pathways, p. 40–156. In J. R. Woodgett (ed.), Protein kinase functions. Oxford University Press, Oxford, England.
   Google Scholar
• Kyriakis, J. M., and J. Avruch. 2001. Mammalian mitogen-activated protein kinase pathways activated by stress and inflammation. Physiol. Rev. 81:807–869.
   PubMed Web of Science ®Google Scholar
• Lang, F., and P. Cohen. 2001. Regulation and physiological roles of serum- and glucocorticoid-induced protein kinase isoforms. Sci. STKE 2001:RE17. [Online.] http://stke.sciencemag.org/cgi/content/full/OC_sigtrans;2001/108/re17.
   PubMedGoogle Scholar
• Lindsey, M. L. 2004. MMP induction and inhibition in myocardial infarction. Heart Fail. Rev. 9:7–19.
   PubMed Web of Science ®Google Scholar
• Lindsey, M. L., G. P. Escobar, L. W. Dobrucki, D. K. Goshorn, S. Bouges, J. T. Mingoia, D. M. McClister, Jr., H. Su, J. Gannon, C. Macgillivray, R. T. Lee, A. J. Sinusas, and F. Spinale. 2005. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis following myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. [Online.] https://doi.org/10.1152/ajpheart.00457.2005.
   Google Scholar
• Ma, Z., R. C. Shah, M. J. Chang, and E. N. Benveniste. 2004. Coordination of cell signaling, chromatin remodeling, histone modifications and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol. Cell. Biol. 24:5496–5509.
   PubMed Web of Science ®Google Scholar
• Malicet, C., V. Giroux, S. Vasseur, J. Dagorn, J. L. Neira, and J. L. Iovanna. 2006. Regulation of apoptosis by the p8/prothymosin α complex. Proc. Natl. Acad. Sci. USA 103:2671–2676.
   PubMedGoogle Scholar
• Mallo, G. V., F. Fiedler, E. L. Calvo, E. M. Ortiz, S. Vasseur, V. Keim, J. Morisset, and J. L. Iovanna. 1997. Cloning and expression of the rat p8 cDNA, a new gene activated in pancreas during the acute phase of pancreatitis, pancreatic development and regeneration, and which promotes cellular growth. J. Biol. Chem. 272:32360–32369.
   PubMed Web of Science ®Google Scholar
• McKinsey, T. A., and E. N. Olson. 2005. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Investig. 115:538–546.
   PubMed Web of Science ®Google Scholar
• Mukherjee, R., T. A. Brinsa, K. B. Dowdy, A. A. Scott, J. M. Baskin, A. M. Deschamps, A. S. Lowry, G. S. Escobar, D. G. Lucas, W. M. Yarbrough, M. R. Zile, and F. G. Spinale. 2003. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107:618–625.
   PubMed Web of Science ®Google Scholar
• Patten, R. D., D. Denofrio, M. El-Zaru, R. Kakkar, J. Saunders, F. Celestin, K. Warner, H. Rastegar, K. R. Khabbaz, J. E. Udelson, M. A. Konstam, and R. H. Karas. 2005. Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J. Am. Coll. Cardiol. 45:1419–1424.
   PubMed Web of Science ®Google Scholar
• Ree, A. H., M. Tvermyr, O. Engebraaten, R. Rooman, O. Rosok, E. Hovig, L. A. Meza-Zepeda, O. S. Bruland, and O. Fodstad. 1999. Expression of a novel factor in human breast cancer cells with metastatic potential. Cancer Res. 59:4675–4680.
   PubMedGoogle Scholar
• Reeves, R., and L. Beckerbauer. 2001. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim. Biophys. Acta 1519:13–29.
   PubMed Web of Science ®Google Scholar
• Rohde, L. E., A. Ducharme, L. H. Arroyo, M. Aikawa, G. H. Sukhova, A. Lopez-Anaya, K. F. McClure, P. G. Mitchell, P. Libby, and R. T. Lee. 1999. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99:3063–3070.
   PubMed Web of Science ®Google Scholar
• Rosenzwieg, A., T. D. Halazonetis, J. G. Seidman, and C. E. Seidman. 1991. Proximal regulatory domains of rat atrial natriuretic factor gene. Circulation 84:1256–1265.
   PubMedGoogle Scholar
• Sato, H., and M. Sieki. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395–405.
   PubMed Web of Science ®Google Scholar
• Seeler, J.-S., and A. Dejean. 2003. Nuclear and unclear functions of SUMO. Nat. Rev. Mol. Cell Biol. 4:690–699.
   PubMed Web of Science ®Google Scholar
• Shin, M., C. Yan, and D. Boyd. 2002. An inhibitor of c-Jun amino-terminal kinase (SP600125) represses c-Jun activation, DNA binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim. Biophys. Acta 1589:311–316.
   PubMed Web of Science ®Google Scholar
• Siwik, D. A., D. L. Chang, and W. S. Colucci. 2000. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ. Res. 86:1259–1265.
   PubMed Web of Science ®Google Scholar
• Spinale, F. G. 2002. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 90:520–530.
   PubMed Web of Science ®Google Scholar
• Su, S. B., Y. Motoo, J. L. Iovanna, M. J. Xie, H. Mouri, K. Ohtsubo, Y. Yamaguchi, H. Watanabe, T. Okai, F. Matsubara, and N. Sawabu. 2001. Expression of p8 in human pancreatic cancer. Clin. Cancer Res. 7:309–313.
   PubMedGoogle Scholar
• Ulrich, H. D. 2005. Mutual interactions between the SUMO and ubiquitin systems: a plea of no contest. Trends Cell Biol. 15:525–532.
   PubMedGoogle Scholar
• Vasseur, S., A. Hoffmeister, S. Garcia, C. Bagnis, J. C. Dagorn, and J. L. Iovanna. 2002. p8 is critical for tumour development induced by ras V12 mutated protein and E1A oncogene. EMBO Rep. 3:165–170.
   PubMedGoogle Scholar
• von Harsdorf, R., J. G. Edwards, Y. T. Shen, R. K. Kudej, R. Dietz, L. A. Leinwane, B. Nadal-Ginard, and S. F. Vatner. 1997. Identification of a cis-acting regulatory element conferring inducibility of the atrial natriuretic factor gene in acute pressure overload. J. Clin. Investig. 100:1294–1304.
   PubMedGoogle Scholar
• Wang, L., and C. G. Proud. 2002. Ras/ERK signaling is essential for activation of protein synthesis by Gq protein-coupled receptor agonists in adult cardiomyocytes. Circ. Res. 91:821–829.
   PubMed Web of Science ®Google Scholar
• Wechman, R. L., C. Gordon, and R. J. Mayer. 2005. Ubiquitin and ubiquitin-like proteins as multifunctional signals. Nat. Rev. Mol. Cell Biol. 6:599–609.
   PubMedGoogle Scholar
• Wilkins, B. J., Y.-S. Dai, O. Bueno, S. A. Parsons, J. Xu, D. M. Plank, F. Jones, T. R. Kimball, and J. D. Molkentin. 2004. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94:110–118.
   PubMed Web of Science ®Google Scholar
• Wilson, E. M., S. L. Moainie, J. M. Baskin, A. S. Lowry, A. M. Deschamps, R. Mukherjee, T. S. Guy, M. G. St. John-Sutton, J. H. Gorman III, L. H. Edmunds, Jr., R. C. Gorman, and F. G. Spinale. 2003. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 107:2857–2863.
   PubMed Web of Science ®Google Scholar
• Yang, J., M. Boerm, M. McCarthy, C. Bucana, I. J. Fidler, Y. Zhuang, and B. Su. 2000. Mekk3 is essential for early embryonic cardiovascular development. Nat. Genet. 24:309–313.
   PubMedGoogle Scholar
• Yarbrough, W. M., R. Mukherjee, T. A. Brinsa, K. B. Dowdy, A. A. Scott, G. P. Escobar, C. Joffs, D. G. Lucas, F. A. Crawford, Jr., and F. G. Spinale. 2003. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J. Thorac. Cardiovasc. Surg. 125:602–610.
   PubMedGoogle Scholar
• Yarbrough, W. M., R. Mukherjee, G. P. Escobar, J. T. Mingoia, J. A. Sample, J. W. Hendrick, K. B. Dowdy, J. E. McLean, A. S. Lowry, T. P. O'Neill, and F. G. Spinale. 2003. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation 108:1753–1759.
   PubMed Web of Science ®Google Scholar
• Yu, Q., and I. Stamenkovic. 2000. Cell surface-localized matrix metalloproteinase-9 proteolytically activates transforming growth factor β and promotes tumor invasion and angiogenesis. Genes Dev. 14:163–176.
   PubMed Web of Science ®Google Scholar